# Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

> **NCT01721655** · PHASE2,PHASE3 · UNKNOWN · sponsor: **West Virginia University Healthcare** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Lung Disease
- Bronchopulmonary Dysplasia

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01721655
- **Lead sponsor:** West Virginia University Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721655, "Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT01721655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*